Claim References

Claim References



Reference Number

Associated Claim


In a prospective, double-blind, placebo-controlled clinical trial, iliadin® Metered Nose Spray (0,05 % m/v) demonstrated a statistically significant reducing of the duration of acute rhinitis by 2 days as compared to physiological saline solution and a mean onset of action after 25 seconds. Reinecke S, Tschaikin M. MMW - Fortschr Med. 2005;147(3):113-118.


Martindale. Thirty-eighth edition. The complete drug reference. Oxymetazoline Hydrochloride. Editor: Thomson Reuters.


Wegener and Grebe. JOURNAL PHARMAKOL. U THER.2012.21;3: 75-80.


IQVIA IMS TPM Data, Volumes, MAT, April 2019, IQVIA South Africa.


Impact Rx, Prescriber Analysis, South Africa, April 2019


iliadin® package leaflet.


Graf, P (2005). “Rhinitis medicamentosa: a review of causes and treatment.” Treatments in respiratory medicine 4(1):21–9


Bergner A, Tschaikin M. Treating rhinitis in babies and toddlers [German Paper]. Apotheker Zeitung 2005;145: 97-99


*iliadin® Metered Nose Spray (0,05 % Oxymetazoline). Indicated for adults and children aged six years and older. Ask your doctor or pharmacist about the iliadin® product that is best suited for your family.


You are about to leave the iliadin® South Africa website and will be redirected to an external website. Would you like to leave?